BBOT

BridgeBio Oncology Therapeutics,…

• TipRanks·05/15 13:15

  Morgan Stanley Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

• TipRanks·05/14 07:40

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arvinas Holding Company (ARVN) and BridgeBio Oncology Therapeutics (BBOT)

• TipRanks·05/14 06:01

  BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks

• TipRanks·05/13 15:20

  Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Century Therapeutics (IPSC)

• TipRanks·05/13 12:16

  Oppenheimer Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

• TipRanks·05/13 11:37

  Piper Sandler Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

• TipRanks·05/12 22:29

  BridgeBio Oncology reports Q1 net loss ($42.1M) vs. ($22.1M) last year

• Benzinga·05/12 21:54

  BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,

• Seeking Alpha·05/12 21:12

  BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$526.11

• Dow Jones·05/12 21:06

  *BridgeBio Oncology Cash Expected to Provide Cash Runway Into 2028 >BBOT

• Dow Jones·05/12 21:06

  *BridgeBio Oncology as of March 31 Cash, Cash Equivalents and Marketable Securities Totaling $388.9M >BBOT

• Dow Jones·05/12 21:05

  *BridgeBio Oncology Thera 1Q Loss/Shr $526.11 >BBOT

• PUBT·05/12 21:03

  BridgeBio Oncology net loss widens to $42.11 million in Q1 FY26

• Reuters·05/12 21:03

  BRIDGEBIO ONCOLOGY THERAPEUTICS INC: CASH RUNWAY EXPECTED TO FUND OPERATIONS INTO 2028

• Dow Jones·05/12 21:03

  Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress